Related Experiment Video
Updated: Jul 14, 2026

Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice
Published on: May 4, 2015
Neuroprotection with or without erythropoiesis; sometimes less is more
1Section of Neuropharmacology, Division of Disease Pharmacology, H Lundbeck A/S, Ottiliavej 9, 2500 Copenhagen, Denmark. LTO@lundbeck.com
Abstract:
Erythropoietin (EPO) is a pleiotropic cytokine with a therapeutic potential that goes well beyond the treatment of anaemia. The study by Wang et al (2007b) examined the protective effects of EPO in a rat model of embolic stroke. The efficacy and haematological side effects of EPO were compared to those of a carbamylated EPO variant (CEPO). Treatment with EPO dose-dependently reduced infarct volume and improved long-term functional outcome. However, an increase in hematocrit was seen even for doses of EPO that did not offer neuroprotection. These data do not suggest the existence of a therapeutic window between effect and side effect for treatment with EPO. Treatment with CEPO was without haematological side effects.
Related Concept Videos
Erythropoiesis
Erythropoiesis
Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Neurogenesis and Regeneration of Nervous Tissue
The Blood-brain Barrier

